Andrew D W Torrance1, L Max Almond2, J Fry2, Martin S Wadley3, Iain D Lyburn4. 1. Department of Upper GI Surgery, Worcestershire Royal Hospital, Worcester, United Kingdom. Electronic address: adwtorrance@doctors.org.uk. 2. Three Counties Upper GI Unit, Gloucestershire Royal Hospitals NHS Foundation Trust, Gloucester, United Kingdom. 3. Department of Upper GI Surgery, Worcestershire Royal Hospital, Worcester, United Kingdom; Three Counties Upper GI Unit, Gloucestershire Royal Hospitals NHS Foundation Trust, Gloucester, United Kingdom. 4. Three Counties Upper GI Unit, Gloucestershire Royal Hospitals NHS Foundation Trust, Gloucester, United Kingdom; Department of Radiology, Cheltenham Hospital, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom.
Abstract
BACKGROUND: Survival in oesophageal cancer remains poor with high post-operative recurrence rates. PET/CT was introduced to the Three-Counties Cancer Network (3CCN) in 2006 to detect 'occult' metastatic disease not seen with conventional staging modalities. This study aims to determine whether the introduction of Integrated fluorodeoxyglucose (18F) Positron Emission Tomography (PET/CT) has changed the management, improved survival or reduced the rate of early post-operative recurrence in patients with operable oesophageal cancer. METHODS: A retrospective review was undertaken of all patients diagnosed with oesophageal cancer in the 3CCN from 2005 to 2009. Early recurrence was defined as proven recurrence locally or at a distant site within one year of resection. RESULTS: 725 patients were identified. 200 (27.6%) patients underwent staging PET/CT. PET/CT altered treatment intent in 19 (9.5%) patients. 128 (17.7%) patients underwent oesophageal resection, 90 (70.3%) of which had a staging PET/CT. No significant difference was noted in post-operative mortality (4.4% Vs 5.3%, p = 0.8) or early recurrence where PET/CT was performed when adjusted for age, sex, stage or neo-adjuvant chemotherapy (p = 0.761, OR 1.136[95% CI 0.499-2.585]). PET/CT had no significant effect on survival (log-rank test; Chi-square 0.710, p = 0.4). CONCLUSION: PET/CT has improved the accuracy of oesophageal cancer staging avoiding potentially unnecessary surgery. Ultimately however, its use has had no effect on early recurrence or survival rates. Inaccurate identification of occult metastatic disease prior to the introduction of staging PET/CT does not appear to be the primary cause of early recurrence in patients with oesophageal cancer.
BACKGROUND: Survival in oesophageal cancer remains poor with high post-operative recurrence rates. PET/CT was introduced to the Three-Counties Cancer Network (3CCN) in 2006 to detect 'occult' metastatic disease not seen with conventional staging modalities. This study aims to determine whether the introduction of Integrated fluorodeoxyglucose (18F) Positron Emission Tomography (PET/CT) has changed the management, improved survival or reduced the rate of early post-operative recurrence in patients with operable oesophageal cancer. METHODS: A retrospective review was undertaken of all patients diagnosed with oesophageal cancer in the 3CCN from 2005 to 2009. Early recurrence was defined as proven recurrence locally or at a distant site within one year of resection. RESULTS: 725 patients were identified. 200 (27.6%) patients underwent staging PET/CT. PET/CT altered treatment intent in 19 (9.5%) patients. 128 (17.7%) patients underwent oesophageal resection, 90 (70.3%) of which had a staging PET/CT. No significant difference was noted in post-operative mortality (4.4% Vs 5.3%, p = 0.8) or early recurrence where PET/CT was performed when adjusted for age, sex, stage or neo-adjuvant chemotherapy (p = 0.761, OR 1.136[95% CI 0.499-2.585]). PET/CT had no significant effect on survival (log-rank test; Chi-square 0.710, p = 0.4). CONCLUSION: PET/CT has improved the accuracy of oesophageal cancer staging avoiding potentially unnecessary surgery. Ultimately however, its use has had no effect on early recurrence or survival rates. Inaccurate identification of occult metastatic disease prior to the introduction of staging PET/CT does not appear to be the primary cause of early recurrence in patients with oesophageal cancer.
Authors: David M Bunting; Wesley W Lai; Richard G Berrisford; Tim J Wheatley; Brent Drake; Grant Sanders Journal: World J Surg Date: 2015-04 Impact factor: 3.352
Authors: N Patel; Kieran G Foley; A G Powell; J R Wheat; D Chan; P Fielding; S A Roberts; W G Lewis Journal: Eur J Nucl Med Mol Imaging Date: 2018-08-16 Impact factor: 9.236
Authors: Chris Harrington; Lyn Smith; Jennifer Bisland; Elisabet López González; Neil Jamieson; Stuart Paterson; Adrian John Stanley Journal: World J Gastrointest Endosc Date: 2018-01-16
Authors: Lucas Goense; Jihane Meziani; Peter S N van Rossum; Frank J Wessels; Marnix G E H Lam; Richard van Hillegersberg; Jelle P Ruurda Journal: Eur Radiol Date: 2017-12-07 Impact factor: 5.315